美罗华联合CTNP方案治疗高龄B细胞非霍奇金淋巴瘤疗效观察

Clinical study on Rituximab combined with CTNP regiment for treatment of elderly patients with non-Hodgkin's lymphoma

目的探讨美罗华联合CTNP方案治疗高龄非霍奇金淋巴瘤的疗效及毒副反应。方法 6例经病理证实为B细胞非霍奇金淋巴瘤高龄患者采用美罗华联合CTNP方案化疗。每3周为1个周期。观察患者治疗过程中及其后的毒副反应和疗效。结果 6例高龄患者完全缓解4例,部分缓解2例,1年总生存率83.33%。毒副反应均可耐受,主要是骨髓抑制和输液相关的不良反应。结论美罗华联合CTNP方案是治疗高龄B细胞非霍奇金淋巴瘤的一种有效方案,完全缓解率高且毒副反应小。

Objective To investigate the efficacy and safety of Rituximab combined with CTNP regiment for treatment of elderly patients with non-Hodgkin＇s lymphoma.Methods 6 elderly patients with B-cell Non-Hodgkin＇s Lymphoma were treated with Rituximab combined with CTNP regiment in our department.The efficacy and safety were evaluated during and after.Results Among 6 elderly patients with B-cell Non-Hodgkin＇s Lymphoma,the complete remission was observed in 4 patients and partial remission was observed in 2 patients.The 1-year survival rates were 83.33%.The major toxic effects were bone marrow suppression and infusion related reaction that all patients could tolerate.Conclusion These results indicate that the Rituximab combined with CTNP regiment is an effective therapy for the elderly patients with non-Hodgkin＇s lymphoma.The complete remission is high and the toxicities are low.